Enfusion Executives
ENFNDelisted Stock | USD 10.76 0.00 0.00% |
Enfusion employs about 1.1 K people. The company is managed by 21 executives with a total tenure of roughly 2667 years, averaging almost 127.0 years of service per executive, having 54.43 employees per reported executive. Analysis of Enfusion's management performance can provide insight into the firm performance.
Enfusion |
Enfusion Management Team Effectiveness
The company has return on total asset (ROA) of 0.0305 % which means that it generated a profit of $0.0305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0442 %, meaning that it created $0.0442 on every $100 dollars invested by stockholders. Enfusion's management efficiency ratios could be used to measure how well Enfusion manages its routine affairs as well as how well it operates its assets and liabilities.Enfusion Workforce Comparison
Enfusion is rated below average in number of employees category among its peers. The total workforce of Information Technology industry is currently estimated at about 32,663. Enfusion holds roughly 1,143 in number of employees claiming about 4% of equities under Information Technology industry.
The company has Profit Margin (PM) of 0.01 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.03 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.03. Enfusion Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enfusion insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enfusion's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Enfusion insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oleg Movchan over three months ago Disposition of 11452 shares by Oleg Movchan of Enfusion at 11.393 subject to Rule 16b-3 | ||
Bradley Herring over three months ago Disposition of 4645 shares by Bradley Herring of Enfusion at 11.375 subject to Rule 16b-3 | ||
Valeria Gutowski over three months ago Disposition of 540 shares by Valeria Gutowski of Enfusion at 11.42 subject to Rule 16b-3 | ||
Bradley Herring over three months ago Acquisition by Bradley Herring of 58202 shares of Enfusion subject to Rule 16b-3 | ||
Oleg Movchan over three months ago Disposition of 150000 shares by Oleg Movchan of Enfusion at 10.09 subject to Rule 16b-3 | ||
Bradley Herring over six months ago Disposition of 24443 shares by Bradley Herring of Enfusion at 10.61 subject to Rule 16b-3 | ||
Neal Pawar over six months ago Disposition of 19226 shares by Neal Pawar of Enfusion at 9.92 subject to Rule 16b-3 | ||
Somers Deirdre over six months ago Acquisition by Somers Deirdre of 13470 shares of Enfusion subject to Rule 16b-3 |
Enfusion Notable Stakeholders
An Enfusion stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Enfusion often face trade-offs trying to please all of them. Enfusion's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Enfusion's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Stephen Dorton | Chief Officer | Profile | |
Michael Berry | Chief Officer | Profile | |
Lorelei Skillman | Chief Officer | Profile | |
Vivek Ranka | Head Technology | Profile | |
Stephen Malherbe | Managing Partner | Profile | |
Oleg Movchan | Interim Director | Profile | |
Matthew Campobasso | General Secretary | Profile | |
Bronwen Bastone | Chief Officer | Profile | |
Joseph Defeo | Global Production | Profile | |
Lotte Tonsberg | Head EMEA | Profile | |
Kabir Kohli | MD Services | Profile | |
Jeff Young | Head Implementation | Profile | |
Iris Wang | Chief Officer | Profile | |
Brian Murphy | Investor | Profile | |
Matt Campobasso | General Counsel | Profile | |
Robert Taylor | Head Support | Profile | |
Ignatius Njoku | Head Relations | Profile | |
Bradley Herring | Chief Officer | Profile | |
Neal Pawar | Chief Officer | Profile | |
Daniel Groman | Chief Officer | Profile | |
Valeria Gutowski | Chief Officer | Profile |
About Enfusion Management Performance
The success or failure of an entity such as Enfusion often depends on how effective the management is. Enfusion management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Enfusion management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Enfusion management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois. Enfusion Inc operates under SoftwareApplication classification in the United States and is traded on New York Stock Exchange. It employs 892 people.
Enfusion Workforce Analysis
Traditionally, organizations such as Enfusion use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Enfusion within its industry.Enfusion Manpower Efficiency
Return on Enfusion Manpower
Revenue Per Employee | 176.4K | |
Revenue Per Executive | 9.6M | |
Net Income Per Employee | 3.4K | |
Net Income Per Executive | 186.4K | |
Working Capital Per Employee | 57.9K | |
Working Capital Per Executive | 3.2M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Enfusion Stock
If you are still planning to invest in Enfusion check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Enfusion's history and understand the potential risks before investing.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
CEOs Directory Screen CEOs from public companies around the world | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |